Molecular-oriented treatment of metastatic kidney cancer
Annales UMCS, Sectio DDD, Pharmacia, Vol. XXIV, N 4, 12
ELŻBIETA STAROSŁAWSKA1, KRZYSZTOF J. CZARNOCKI1,2,
TOMASZ KUBIATOWSKI1, JUSTYNA SZUMIŁO3,FRANCISZEK BURDAN4
1 Department of Chemotherapy, St John’s Cancer Center, Lublin, Poland
2 Occupational Hygiene and Ergonomics Dept., Lublin University of Technology, Lublin, Poland
3 Department of Clinical Pathomorphology, Medical University in Lublin, Poland
4 Radio-Diagnostic Dept., St John’s Cancer Center, Lublin, Poland
According the latest trial results, chemotherapy and hormone treatment of metastatic kidney cancer seems to be ineffective. The most recent study results show that the response to treatment is on the level of statistical error – 5%, chemotherapy lacks effectiveness. The analysis of the effectiveness of specified drugs resulted in failure.
The paper presents the treatment characteristics – treatment and recommendation levels of metastatic kidney cancer, as well as effectiveness of different treatment algorithms.
In conclusion we stated that the introduction of new drugs oriented toward the molecular treatment improved the prognosis for the patients suffering from metastatic renal cell carcinoma. During the period of molecular treatment statistically significant prolongation of the survival time has been achieved.
Files to download
metastatic kidney carcinoma, therapies, hormone treatment, prognostic factors